December 31, 2021
Emcure Pharmaceuticals to launch oral Covid-19 drug in a week’s time in India
A toll free helpline to be set up to help doctors and patients
Pune, December 31 2021: Emcure Pharmaceuticals Limited (EPL) announced that it has received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the launch of Molnupiravir, an investigational oral anti-viral drug, for the treatment of mild COVID-19. EPL plans to launch Molnupiravir under the brand name Lizuvira in the Indian market.
As the need for such a drug is imminent in the face of emerging challenges in COVID- 19 treatment, EPL will endeavour to deliver Lizuvira (Molnupiravir) in a week’s time. A toll-free Helpline will be dedicated to help the doctors and patients access the product.
Earlier this year, EPL had entered into a licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).
Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. The drug, being developed by MSD and Ridgeback Biotherapeutics has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (US FDA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.
“Emcure Pharmaceuticals Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated August 18, 2021 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the websites of SEBI, Axis Capital Limited, Credit Suisse Securities (India) Private Limited, BofA Securities India Limited, JM Financial Limited and BOB Capital Markets Limited at www.sebi.gov.in, www.axiscapital.co.in, www.credit-suisse.com, www.mlindia.com, www.jmfl.com and www.bobcaps.in, respectively. Investors should note that investment in equity shares involves a high degree ofrisk and for details refer to the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for any investment decision.”
“The Equity Shares offered in the initial public offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.”
About Emcure Pharmaceuticals Ltd.:
Emcure Pharmaceuticals Ltd. (EPL) is one of the leading Indian pharmaceutical companies (Source: Report titled “Assessment of the global and Indian pharmaceuticals industry” dated August 2021, prepared by CRISIL Research) headquartered in Pune with global footprint. Driven by strong in-house research and development with focus on technology and innovation, EPL’s mission has been to develop a differentiated portfolio of pharmaceutical products and address unmet patient needs. Established in 1981, the firm was founded by Mr. Satish Mehta and is ranked as the 12 th largest pharmaceutical company in India (Source: CRISIL). It is the largest pharmaceutical company in India in gynaecology, blood-related and HIV antiviral therapeutic areas based on sales in India in the Financial Year 2021 (Source: CRISIL). Emcure Group is also in the process developing India’s first mRNA COVID19 vaccine for the novel coronavirus using its in-house developed indigenous mRNA platform. To know more about EPL, please visit: https://www.emcure.com/ Follow us on LinkedIn: https://www.linkedin.com/company/emcure-pharmaceuticals-limited/
Media Contact Information:
Aasiya Shaikh: 9833503994
Syed Talal: 9987619679
To know more about Emcure, please visit:
Follow us on LinkedIn:
Media Contact Information:
Aasiya Shaikh: 9833503994 (Adfactors PR)
Syed Talal: 9987619679 (Adfactors PR)
Naveen Soni: email@example.com (Corporate Communications)